These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26412802)

  • 1. Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects.
    Sturm-Pellanda C; Abt M; Sanwald-Ducray P; Schmitt C
    Clin Ther; 2015 Nov; 37(11):2439-48. PubMed ID: 26412802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).
    Calara F; Taylor K; Han J; Zabala E; Carr EM; Wintle M; Fineman M
    Clin Ther; 2005 Feb; 27(2):210-5. PubMed ID: 15811484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.
    Hövelmann U; Heise T; Nosek L; Sassenfeld B; Thomsen KMD; Haahr H
    Clin Drug Investig; 2017 May; 37(5):503-509. PubMed ID: 28185141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.
    Kapitza C; Heise T; Birman P; Jallet K; Ramis J; Balena R
    Diabet Med; 2009 Nov; 26(11):1156-64. PubMed ID: 19929995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus.
    Plum-Mörschel L; Andersen LR; Hansen S; Hövelmann U; Krawietz P; Kristensen NR; Lehrskov LL; Haahr H
    Clin Drug Investig; 2023 Feb; 43(2):119-127. PubMed ID: 36631720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
    Wang EQ; Plotka A; Salageanu J; Sattler C; Yunis C
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites.
    Leohr JK; Dellva MA; LaBell E; Coutant DE; Linnebjerg H
    Clin Ther; 2022 Jun; 44(6):836-847. PubMed ID: 35577602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study.
    Krop J; Kramer WG
    Clin Ther; 2017 Dec; 39(12):2345-2354. PubMed ID: 29191450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects.
    Tiessen RG; Castaigne JP; Dreyfus JF; Nemansky M; Kruizinga HH; van Vliet AA
    Int J Clin Pharmacol Ther; 2008 Sep; 46(9):443-52. PubMed ID: 18793574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial.
    Heise T; Nosek L; Dellweg S; Zijlstra E; Præstmark KA; Kildegaard J; Nielsen G; Sparre T
    Diabetes Obes Metab; 2014 Oct; 16(10):971-6. PubMed ID: 24720741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
    Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
    Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.
    Kotani N; Yoneyama K; Kawakami N; Shimuta T; Fukase H; Kawanishi T
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):702-712. PubMed ID: 30230257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
    Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
    Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
    Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
    Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
    Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
    Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.
    Bogman K; Brumm J; Hofmann C; Giraudon M; Niggli M; Sturm-Pellanda C; Sauter A; Sturm S; Mangold B; Schmitt C
    Clin Pharmacokinet; 2019 Sep; 58(9):1205-1214. PubMed ID: 30968335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.
    Henry RR; Mudaliar S; Kanitra L; Woloschak M; Balena R;
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2370-9. PubMed ID: 22539590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.